Locations:

Acute Stroke Care: How Thinking About Timeliness and Treatment Options Has Evolved (Podcast)

Check out one of the first episodes of our ‘Neuro Pathways’ podcast

Eighteen minutes of catching up on developments in the acute treatment of ischemic stroke. That’s what’s in store from one of the first episodes of Cleveland Clinic Neurological Institute’s new “Neuro Pathways” podcast for healthcare professionals.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Podcast host Alex Rae-Grant, MD, asks interventional neurologist M. Shazam Hussain, MD, Director of Cleveland Clinic’s Cerebrovascular Center, to debrief him on the recent evolution of acute stroke management. They cover a number of topics, with Dr. Hussain sharing perspectives on the following:

  • Factors he weighs when considering both thrombolytic therapy and endovascular therapy
  • Pros and cons of the two main techniques for mechanical thrombectomy
  • Refinements in our understanding around appropriate time windows for endovascular therapy
  • How the emergence of stroke systems of care will better meet the challenge of quickly getting patients to the hospital best matched to their needs in the era of endovascular therapy

Here’s a short sample of their exchange:

Dr. Rae-Grant: Let’s say I have an acute ischemic stroke. How many hours out could you potentially do an endovascular intervention?

Dr. Hussain: The thinking on this has changed a lot over time. Initially we were very time-based and had strict time windows. We used to say we could offer mechanical thrombectomy only within the first six hours after stroke symptom onset. That was largely due to fear of potentially causing hemorrhagic transformation once the blood vessel was opened, with possible bleeding into the brain resulting from the restored blood flow. With time we have found that we are able to use imaging modalities to identify patients who have a small core infarction as well as a lot of brain that can be saved irrespective of where they are in the time window. Those patients’ blood vessels can still be safely opened up beyond the six-hour window with what seems to be a quite low risk of hemorrhagic transformation.

Advertisement

As a result, in contrast to offering therapy in just the first six hours, we now have clinical trials that have established that offering therapy up to 16 and 24 hours after symptom onset is a safe paradigm and is actually highly effective in improving patients’ outcomes. In fact, there even have been cases where patients with a small core infarction and a large area with lack of perfusion (indicating a lot of penumbral tissue to be saved) have had blood flow successfully restored after more than 24 hours have passed since symptom onset.

Listen to the full 18-minute podcast on the player below. Check out more of Cleveland Clinic’s “Neuro Pathways” podcast episodes at clevelandclinic.org/neuropodcast or subscribe wherever you get your podcasts.

Advertisement

Related Articles

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

23-NEU-3627359-CQD-Hero-650×450

6 Things to Know About the New Home of Our Neurological Institute

Designed for digitization, distance health, discovery and more

illustration of a bright clinical room with clinicians inside

Inside Our Neurological Institute’s Next-Generation Advanced Therapeutics Space

Combining customized care, research capabilities and flexibility for the future

stylized illustration of human brain made up of cogs and wheels
October 9, 2026/Neurosciences/Brain Health

How Alzheimer’s Disease Studies Need to Evolve in the Targeted Therapy Era

Leading investigators outline a new roadmap for clinical trials and observational research

Older man tending to houseplants

TEMPO-2 Trial Shows Promise for Tavapadon in Newly Diagnosed Parkinson’s Disease

The selective D1/D5 dopamine agonist provides symptom relief and improves daily function.

illustration of human brain with swirls of activity inside it
September 23, 2026/Neurosciences/Brain Health

Cleveland ADRC Renewal Boosts Research Into Alzheimer’s Progression

5-year funding award supports cohort expansion and deep phenotyping of AD and related dementias

young man meditating on a sofa
September 21, 2026/Neurosciences/Epilepsy

Lifestyle Interventions Show Promise as Adjunctive Epilepsy Management

Highest response rates seen with stress-lowering techniques like yoga, meditation and mindfulness

Ad